<div class=WordSection1>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><b><span style='font-size:20.0pt;
font-family:"Helvetica","sans-serif"'>Poster Session I:</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span style='font-size:12.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:navy'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:12.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:navy'>Perrine Borel, Engineer</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, CNRS, 1, rue de l’Internationale, 91000 Evry, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>borel@genethon.fr<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Imaging Techniques for
Membrane Tears Assessment in Dysferlin-Deficient Models</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Perrine Borel <sup>1</sup>, Jessica Petiot <sup>1</sup>, Edouard
De Dreuzy <sup>1</sup>, <sup>1</sup>, Joseph Roche <sup>2</sup>, Robert Bloch <sup>2</sup>,
Isabelle Richard <sup>1</sup>, Daniel Stockholm <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Généthon, CNRS, 1, rue de
l’Internationale, 91000 Evry, France; <sup>2</sup>In Vivo Departement,
Généthon, 1, rue de l’Internationale, 91000 Evry, France; <sup>3</sup>University
of Maryland Baltimore, Baltimore, MD, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=131
src="poster-abstracts-images/image001.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=22"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Membrane tears in dysferlin deficient muscle fibers are the
effects of a physiologic response to particular mechanic stress like
lengthening contractions. Sarcolemmal membrane disruption can either lead to
fiber necrosis or repair but little is known about the size and the kinetics of
formation of the tears. To study this, we subjected dysferlin-deficient mice
tibialis anterior muscle to eccentric exercise –either with downhill running on
treadmill or induced lengthening contraction inspired from Bloch and al– to
investigate several aspects of the formation of membrane tears. We previously
estimated the size of membrane rips to be under 10µm using a size exclusion
strategy based on the penetration into the damaged fibers of circulating
fluorescent dextrans. In this work, we describe the frequency and location of
tears in 6, 12 and 18 month old mice, as well as the muscle tissue composition
transformation following exercise. To explore the spatial dimension, we attempted
to couple the Large Strain Injury (LSI) device from the Bloch lab with
macroconfocal imaging to observe the tearing process in real time. This set up
should be helpful in following the membrane resealing after tearing in-situ
muscle in a living mouse, but is limited in its spatial resolution. To overcome
this limitation, a similar approach was developed in vitro for isolated
extensor digitorum brevis (EDL) muscle which consists of a controlled
stimulating unit enabling the muscle contraction while it is lengthening
simultaneously. We hope to give new insights on the dynamics of the mechanisms
of generation and resealing of membrane tears in a dysferlin deficient context.
</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in;margin-right:0in;margin-bottom:0in;margin-left:.25in;
margin-bottom:.0001pt;text-indent:-.25in'><span style='font-size:12.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:navy'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:12.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:navy'>Alexis Demonbreun, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Medicine, The University of Chicago</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>emcnally@uchicago.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Ferlin Proteins Regulate
Multiple Membrane Fusion Events in Muscle</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Elizabeth McNally <sup>1</sup>, Avery D Posey <sup>1</sup>, Peter
Pytel <sup>2</sup>, Alexis R Demonbreun <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Medicine, The University of
Chicago; <sup>2</sup>Department of Pathology, The University of Chicago</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=105
src="poster-abstracts-images/image002.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=21"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The mammalian ferlins are C2 domain-containing proteins that bind
negatively charged phospholipids in response to calcium. Membrane trafficking
and membrane fusion are key steps for myoblast fusion and muscle membrane
resealing, respectively. Myoferlin is highly expressed in singly nucleated
myoblasts while dysferlin expression is more abundantly expressed in mature,
multinucleated myotubes. In addition, myoferlin mediates endocytic recycling,
and specifically plays a role in trafficking receptors back to the surface of
cells. Insulin like growth factor (IGF) is a potent stimulus of muscle growth.
Myoferlin null muscle is smaller than normal muscle, and we found that
myoferlin null muscle does not respond to IGF1. In vivo after IGF1 infusion, control
muscle increased myofiber diameter by 25%, but myoferlin null muscle was
completely unresponsive. Myoblasts cultured from myoferlin null muscle and
treated with IGF1 also failed to show the expected increase in fusion to
multinucleate myotubes. The IGF1 receptor was found to colocalize with
myoferlin at sites of myoblast fusion. The lack of IGF1 responsiveness in
myoferlin null myoblasts was linked directly to IGF1 receptor mistrafficking as
well as decreased IGF1 signaling. In myoferlin null myoblasts, the IGF1
receptor accumulated into large vesicular structures. These vesicles
colocalized with a marker of late endosome/lysosomes, LAMP2, specifying
redirection from a recycling to a degradative pathway. We now have
characterized a novel member of the ferlin family, Fer1l5, because of its high
homology to dysferlin and myoferlin. We found that Fer1l5 protein is expressed
in nascent myotubes containing only 2-4 nuclei. Therefore, multiple ferlin
proteins contribute to membrane trafficking and fusion events essential for
normal muscle function. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>5. Kerry Fuson, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, Texas Tech Health Science Center,
Lubbock, TX, USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:kerry.fuson@ttuhsc.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>kerry.fuson@ttuhsc.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Structural Characterization
of Human Dysferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Kerry Fuson <sup>1</sup>, Danijela Dukovski <sup>2</sup>, Tom Walz
<sup>2</sup>, Bryan Sutton <sup>1</sup></span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, Texas Tech
Health Science Center, Lubbock, TX, USA; <sup>2</sup>HHMI and Harvard Medical
Center, Boston, MA. USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=137
src="poster-abstracts-images/image003.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=66"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Dysferlin has been implicated in Ca2+ dependent membrane repair of
muscle tissue. Dysferlin deficient mice are unable to effectively repair normal
damage to muscle tissue membranes. Various mutations in the dysferlin gene lead
to limb-girdle muscular dystrophy type 2B and Miyoshi myopathy. Both diseases
are characterized by progressive weakness and wasting of various voluntary
skeletal muscles. Currently, knowledge of dysferlin and its role in the disease
is limited. Using secondary structural analysis, dysferlin likely contains
seven C2 domains (C2A – C2G) and two domains that have yet to be fully
characterized (dys F and dys N). At least some of the C2 domains of dysferlin
are likely involved in Ca2+ dependent membrane interaction, two (C2A and C2F)
have been shown to bind calcium ion. The ultimate goal of our project is to
structurally characterize the dysferlin protein to better understand its role
in muscle repair. To accomplish this, we will acquire high resolution X-ray
crystal structures of each individual C2 domain, as well as an EM
reconstruction of the cytosolic portion of the full length dysferlin protein.
We have successfully cloned all of the C2 domains of human dysferlin and have
solved the X-ray crystal structure of the C2A domain. The C2F domain is
expressed, purified and currently in crystal trials. In addition to the
structural characterization of the individual domains, we are working in
collaboration with Dr. Tom Walz at Harvard Medical School to obtain structural
information of the full length protein. His lab has successfully expressed and
purified the full length protein and has obtained preliminary images of single
particles of full length human dysferlin using EM. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>7. Renzhi Han, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Cell and Molecular Physiology, Loyola University
Medical Center, Maywood, IL 60153</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>renhan@lumc.edu<span
class=email><span style='color:black'> </span></span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>A Single-Molecule Optical
Approach to Study the Function of Dysferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Renzhi Han <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Cell and Molecular
Physiology, Loyola University Medical Center, Maywood, IL 60153</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=125 height=124
src="poster-abstracts-images/image004.jpg"
align=left hspace=12 alt="Description: Renzhi Han.jpg"><span style='font-size:
9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Dysferlin is a
transmembrane protein of ~230 kDa. The large size of dysferlin makes it
difficult to study the protein structure. Single-molecule spectroscopic
techniques emerged in the past decade have greatly enhanced our understanding
of individual biological macromolecules. We propose to use a new
single-molecule optical approach to study the function of dysferlin in solution
and in cells: fluctuation correlation spectroscopy (FCS). FCS measures the
fluctuations of fluorescent light intensity caused by the diffusion of the
molecules and/or complexes through a small observation volume (&lt; 1 µm<sup>3</sup>),
formed by the focus of a confocal microscope. A statistical auto-correlation
analysis of these fluctuations provides information on the diffusion rate of
the molecules and therefore on their size and the properties of the
environment. Furthermore, a quantitative cross-correlation analysis of the
fluctuations provides the dynamic information of the system when combined with
fluorescence resonance energy transfer (FRET). We have begun to decipher
dysferlin interactions using this exciting approach.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>9. Bradley L Hodges, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Prothelia Inc</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:bradhodges@prothelia.com"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>bradhodges@prothelia.com</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Evaluation of Laminin-111 as
a Therapeutic in the mdx Mouse Model of DMD</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Bradley L Hodges <sup>1</sup>, Kate A Hawkins <sup>1</sup>,
Jachinta E Rooney <sup>2</sup>, Dean J Burkin <sup>2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Prothelia Inc; <sup>2</sup>University of
Nevada, Reno</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=127
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=19"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=19"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Among the many isoforms of laminin the laminin-211 isoform
predominates around normal skeletal and cardiac muscle cells and contributes to
the structural integrity of muscle through engagement of the laminin receptors
alpha dystroglycan and alpha7beta1 integrin. Systemic delivery of laminin-111,
an isoform closely related to laminin-211, targets skeletal and cardiac muscles
of the mdx mouse model of human Duchenne muscular dystrophy (DMD), and
stabilizes the muscles of mdx mice through increased synthesis and binding of
the alpha7beta1 integrin. We have found that a single administration of
laminin-111 to mdx mice resulted in reduced serum levels of ALT, AST and CK by
4 days post-injection and increased expression of the alpha7beta1 integrin.
Chronic administration of laminin-111 to mdx mice improved forelimb grip
strength, protected the quadriceps from the damaging effects of downhill
treadmill exercise, and improved force retention in the diaphragm and EDL
muscles following ex vivo eccentric contractions. Chronic dosing of laminin-111
also demonstrated low or nonexistent antibody responses, and kidney function
was not compromised as assessed by serum BUN and creatinine. These data will be
presented including our efforts to produce human recombinant laminin-111 for
treatment of DMD.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>11. Nick Ieronimakis, BS</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Pathology, University of Washington, Seattle, WA,
USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>imax80@u.washington.edu<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Effects of Dysferlinopathy on
Satellite Cell Activation and Fusion.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Nick Ieronimakis <sup>1</sup>, Gayathri Balasundaram <sup>1</sup>,
Morayma Reyes <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Pathology, University of
Washington, Seattle, WA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=75
src="poster-abstracts-images/image005.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=62"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>We have recently demonstrated the role of two satellite cell
populations during muscle regeneration following acute injury (Ieronimakis et
al. PLOS One, 2010). CD34+ satellite cells are quiescent (reserve) cells
whereas CD34- cells are more committed (advanced) satellite cells. Following
acute injury with cardiotoxin (CTX), CD34- cells massively proliferate,
differentiate (demonstrated by high levels of myogenin) and fuse to form new
muscle fibers. We have studied the levels of dysferlin in these two satellite
cell populations. Dysferlin is expressed mainly on activated CD34- cells. By
Flow Cytometry analysis the proportion of satellite cells is not only reduced
but the percentage of CD34- satellite cells was greater in adult A/J vs. Bl6
mice. Both sorted CD34+/- satellite cell populations isolated from A/J mice
were successfully transfected in vitro with a lentiviral vector carrying
dysferlin. Restoration of dysferlin expression appeared to increase satellite
cell fusion capacity. We propose that dysferlin is important for satellite cell
activation and fusion but may not be necessary for maintenance of quiescent
satellite cells. In turn, the number of quiescent satellite cells is decreased
as muscle is continuously being repaired. Therefore we hypothesize that
dysferlin is important for the function and myogenic progression of activated
satellite cells. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>13. Rinse Klooster, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>1 Center for Human Genetics, Leiden University Medical Center,
Leiden, The Netherlands</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:r.klooster@lumc.nl"><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>r.klooster@lumc.nl</span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Affinity Tools for the
Specific Detection of Dysferlin Protein Domains</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Laure Grand Moursel <sup>1</sup>, Antoine de Morree <sup>1</sup>,
Rinse Klooster <sup>1</sup>, Silvere M van der Maarel <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>1 Center for Human Genetics, Leiden
University Medical Center, Leiden, The Netherlands</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=114
src="poster-abstracts-images/image006.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=16"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Defects in the DYSF gene underlie several progressive myopathies
including, Limb-Girdle Muscular Dystrophy 2B and Miyoshi Myopathy. Dysferlin
was shown to be critically important for patch-fusion repair of the muscle
membrane. However, in the past few years, the picture has become increasingly
complex and the precise role of dysferlin in skeletal muscle and myogenesis,
and its relation to muscular dystrophy is still largely unresolved. Dysferlin
is a largely cytosolic protein that anchors to the muscle membrane through a
single pass transmembrane domain. The 230 kDa large dysferlin protein contains
seven intracellular C2 domains as well as several other domains that are
conserved between ferlin proteins. Several proteins have been identified to
interact with dysferlin, but comprehensive insight in the dysferlin protein
complex and its spatiotemporal dynamics is missing. Critically important for
understanding the role of dysferlin in vivo is the availability of well
characterized affinity binders. Several antibodies for dysferlin are
(commercially) available but their application spectrum is limited and often
their specificities and affinities are poorly defined strongly compromising
dysferlin protein studies. We deployed an alternative recombinant affinity
binder technology for our research objectives based on phage display of minimal
antigen recognition fragments (VHH) of llama single chain antibodies. We will
discuss recent advancements on the immunization and selection strategies we
developed for Dysferlin in order to generate a comprehensive set of affinity
binders for Dysferlin, and present affinity binders specific for the Dysferlin
C2E domain. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>15. Angela Lek, BS</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute for Neuroscience and Muscle Research, The Children’s
Hospital at Westmead, Locked Bag 4001, Sydney, NSW 2145, Australia.</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>angela.lek@gmail.com<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Investigating how Dysferlin
Affects Membrane Repair</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Angela Lek <sup>1,2</sup>, Frances J Evesson <sup>1,2</sup>,
Joanne Hawkes <sup>1</sup>, Frances A Lemckert <sup>1,2</sup>, Fabienne Brilot <sup>1</sup>,
Russell C Dale <sup>1</sup>, Kathryn N North <sup>1,2</sup>, Sandra T Cooper <sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Institute for Neuroscience and Muscle
Research, The Children’s Hospital at Westmead, Locked Bag 4001, Sydney, NSW
2145, Australia.; <sup>2</sup>Discipline of Paediatrics and Child Health,
Faculty of Medicine, University of Sydney, Sydney, Australia.</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=128
src="poster-abstracts-images/image007.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=25"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Dysferlin
is thought to play a key role in calcium-activated membrane repair, though how
dysferlin affects this process is unclear.  We have developed two membrane
repair assays to help us investigate how dysferlin expression levels influence
membrane repair, and how the presence or absence of dysferlin modulates
recruitment of other membrane repair proteins.<span style='color:black'> </span>The
first membrane repair assay employs detergent-based damage of whole cell
populations for analysis via flow cytometry. This quantative approach was used
to compare the membrane repair capacity of dysferlin knock-down and dysferlin
over-expressing cells. Interestingly, dysferlin knock-down cells (&lt;15%
normal levels of dysferlin) show only a modest resealing defect, cells moderately
over-expressing dysferlin (2-3 fold upregulation) show no enhanced resealing
capacity, and, cells over-expressing high levels of dysferlin (&gt;4-5 fold)
show a profound defect in resealing capacity. Our results suggest that low
levels of dysferlin expression may be sufficient to bestow near-normal plasma
membrane resealing with moderate injury, whereas significant overexpression of
dysferlin is detrimental to membrane resealing.  The second membrane repair
assay employs ballistics damage; shooting silica microparticles at high
velocity.  The approach induces reproducible and readily defined sites of
membrane damage across a cell population, facilitating assessment of
recruitment, time-frame, and calcium-dependency of membrane repair complex
nucleation. Ballistics studies, and results from flow cytometry, show no
evidence for exocytic recruitment of dysferlin following membrane injury. These
data suggest that existing plasma membrane dysferlin activates acute membrane
resealing, and/or, that other functions of dysferlin underpin its involvement
in membrane resealing.  Both MG53 and annexin-A1 show recruitment to sites of
damage, and we have recently identified a vesicle marker highly enriched at
sites of damage, perhaps highlighting one population of membrane repair
vesicles acutely recruited to membrane lesions</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>17. Monkol Lek, BS</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute for Neuroscience and Muscle Research, The Children’s
Hospital at Westmead, Locked Bag 4001, Sydney, NSW 2145, Australia.</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:monkol.lek@gmail.com"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>monkol.lek@gmail.com</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Phylogenetic Analysis of
Ferlin Genes Reveals Ancient Eukaryotic Origins</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Monkol Lek <sup>1,2</sup>, Angela Lek <sup>1,2</sup>, Kathryn N
North <sup>1,2</sup>, Sandra T Cooper <sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Institute for Neuroscience and Muscle
Research, The Children’s Hospital at Westmead, Locked Bag 4001, Sydney, NSW
2145, Australia.; <sup>2</sup>Discipline of Paediatrics and Child Health,
Faculty of Medicine, University of Sydney, Sydney, Australia.</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=75
src="poster-abstracts-images/image008.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=24"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The ferlin gene family possesses a rare and identifying feature
consisting of multiple tandem  C2 domains and a C-terminal transmembrane
domain. Much currently remains unknown about the fundamental function of this
gene family; however, mutations in its two most well- characterised members,
dysferlin and otoferlin, have been implicated in human disease. Ferlin genes
were detected from all species of representative phyla, with two ferlin
subgroups partitioned within the ferlin phylogenetic tree based on the presence
or absence of a DysF domain. Invertebrates generally possessed two ferlin
genes, while most vertebrates have six ferlin genes. Common to almost all
ferlins is an N-terminal C2-FerI-C2 sandwich, a FerB motif, and two C-terminal
C2 domains adjacent to the transmembrane domain. Preservation of these
structural elements throughout eukaryotic evolution suggests a fundamental role
of these motifs for ferlin function. In contrast, DysF, C2DE, and FerA are
optional, giving rise to subtle differences in domain topologies of ferlin
genes. Despite conservation of multiple C2 domains in all ferlins, the
C-terminal C2 domains displayed higher sequence conservation and greater
conservation of putative calcium binding residues across paralogs and
orthologs. Interestingly, the two non-mammalian ferlins in the model organisms,
C. elegans and D. melanogaster, present as outgroups in the phylogenetic
analysis. Our analysis highlights the existence of ferlin-like proteins
throughout eukaryotic evolution, from unicellular organisms through to humans.
We characterise the preservation of C2 domains and also the poorly
characterised ferlin-specific motifs representing the DysF, FerA and FerB
domains. Our data suggest an ancient role of ferlin proteins, which may have a
role relating to vesicle fusion and plasma membrane specialization. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>19. Cleo Leung, M.Sc.</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>UBC James Hogg Research Centre, Providence Heart + Lung Institute,
St. Paul’s Hospital and Department of Anesthesiology, Pharmacology and
Therapeutics, University of British Columbia, Vancouver, Canada</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>cleo.leung@rogers.com<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Regulates Vascular
Endothelial Cell Adhesion and Growth</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Cleo Leung <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>UBC James Hogg Research Centre,
Providence Heart + Lung Institute, St. Paul’s Hospital and Department of
Anesthesiology, Pharmacology and Therapeutics, University of British Columbia,
Vancouver, Canada</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=115 height=112
src="poster-abstracts-images/image009.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=26"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>While Dysferlin is well-known to regulate plasma membrane
integrity and its mutation leads to the onset of muscular dystrophy, changes in
Dysferlin activity or expression have been reported in preeclampsia,
Alzheimer’s disease and multiple sclerosis. These studies indicate that
Dysferlin is also essential for normal physiological function in non-muscle
cells. We have previously shown in proteomic analysis of caveolae/lipid rafts
that vascular endothelial cells (EC) express another member of the Ferlin
family, Myoferlin, which mediates plasma membrane translocation of vascular
endothelial growth factor receptor-2 (VEGFR2). Herein, we extended our
investigation to examine whether Dysferlin has similar roles as Myoferlin in
VEGFR2 signalling. We found that cultured EC, intact and diseased blood vessels
of rodent and human origin all express Dysferlin. Unlike Myoferlin, presence of
Dysferlin does not regulate VEGFR2 signaling, as Dysferlin gene silencing does
not decrease VEGFR2-dependent nitric oxide release and Erk1/2 phosphorylation.
Instead, loss of Dysferlin in EC results in cell adhesion deficiency,
detachment and growth arrest in sub-confluent cells. Remarkably, confluent EC
monolayers are resistant to cell detachment. In addition, we found that loss of
Dysferlin causes poly-ubiquitination and proteasomal degradation of platelet
endothelial cellular adhesion molecule-1 (PECAM1/CD31), a molecule important in
cell attachment. This loss of adhesion is rescued by an adenovirus encoding for
PECAM1. Our results identify Dysferlin as a regulator of basic endothelial cell
physiology. This broadens the functional scope of the Ferlin protein family. We
propose that Ferlins are heterogeneous in their capacity to regulate different
membrane remodeling events, a likely consequence of their ability to regulate
the fusion of membrane vesicles containing unique protein cargo.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>21. William LOSTAL, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Genethon, CNRS, 1, rue de l’Internationale, 91000 Evry, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:lostal@genethon.fr"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>lostal@genethon.fr</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify;line-height:normal'><b><span lang=EN-GB style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify;line-height:normal'><b><span lang=EN-GB style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Assays for Membrane Repair Evaluation in
Dysferlin-Deficient Myofibers</span></b></p>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>William Lostal <sup>1</sup>, </span></span><span lang=EN-GB
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Perrine Borel<sup>1</sup>,
Edouard De Dreuzy<sup>1</sup>, Daniel Stockholm<sup>1</sup></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Genethon, CNRS, 1, rue de
l’Internationale, 91000 Evry, France</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=149
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=33"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=33"><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>Deficiency in membrane repair is a hallmark of
dysferlin-deficient muscles. Evaluation of this deficit was usually performed
using a laser-wounding assay. In this project, we investigated membrane resealing
of dysferlin-deficient fibers following two different treatments: hypotonic
shock and application of the </span><span style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif";color:#0D0D0D'>bacterial toxin: </span><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>Streptolysin O (SLO). It was previously shown that </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>membrane blebbing in myotubes in response to hypotonic shock
requires dysferlin <sup>1</sup></span><span lang=EN-GB style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:#0D0D0D'>. Here, we
applied a hypotonic solution to isolated muscle fibers. Systematic blebs were
observed immediately after dilution of the medium in both dysferlin-deficient
and C57Bl6 fibers. It seems therefore that myofibers do not require dysferlin
to generate blebs. It is also known that membrane resealing of transmembrane
pore induced by SLO is a Ca2+ dependant endocytic process as it is after
mechanical wounds <sup>2</sup>. We wanted to investigate whether dysferlin is
implicated in repair after pore formation. The conditions for obtaining
membrane wounding by treatment with SLO were optimized to obtain an imaging
kinetic of the entry of propidium iodide and FM1-43. Strong heterogeneity in the
response to such treatment was obtained but no clear evidence of a significant
difference between dysferlin deficient and wild type fibers was yet observed. </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>For both assays, we could not differentiate any specific
response between dysferlin-deficient and C57Bl6 fibers. Whether a difference
could be obtained by exploring other technical conditions or whether this
absence of difference is due to the phenotypic specificity of isolated fibers
(compared to myotubes) remains to be investigated. </span><span lang=FR
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>1.Wang et al. J Appl Physiol 2010 2.Idone et al. </span><span
lang=EN-GB style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:#0D0D0D'>J Cell Biol 2008</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>23. Antoine de Morrée, MSc</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>1 Center for Human Genetics, Leiden University Medical Center,
Leiden, The Netherlands</span></span><span style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>a.de_morree@lumc.nl<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Function in Human
Monocytes</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Antoine de Morrée <sup>1</sup>, Jun Wang<sup>2</sup>, Ivana
Bagaric<sup>2</sup>, Rune R Frants<sup>1</sup>,  Eduard Gallardo <sup>3</sup>,
Isabel Illa<sup>3</sup>, Ren Toes<sup>2</sup>, Silvère M. van der Maarel <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>1 Center for Human Genetics, Leiden
University Medical Center, Leiden, The Netherlands</span>;<span
class=affiliations1><sup> 2</sup>Department of Rheumatology, Leiden University
Medical Center, Leiden, The Netherlands;<sup> 3</sup> Laboratori de Neurologia
Experimental, Hospital de la Santa Creui Sant Pau, Barcelona, Spain</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=122
src="poster-abstracts-images/image010.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=9"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Dysferlin
is mutated in a group of muscular dystrophies commonly referred to as
Dysferlinopathies. It is highly expressed in skeletal muscle, where it is
important for sarcolemmal repair. Recent studies showed that Dysferlin is also
expressed in monocytes. Moreover, muscle of Dysferlinopathy patients is
characterized by a massive immune cell infiltrate. Dysferlin negative monocytes
were shown to be more aggressive and phagocytose an increased number of
particles. It has therefore been suggested that Dysferlin deregulation in
monocytes contributes to disease progression, but the molecular mechanism is
unclear. Here we show that Dysferlin protein expression is increased with
differentiation in human monocytes and the THP1 monocyte cell model. Adhesion
assays indicate that this increased expression is independent of cell-matrix
contact formation. In contrast, Dysferlin is further increased upon the
formation of cell-cell contacts. This might suggest a function of Dysferlin in
monocyte cell contacts. In future studies we aim to dissect the role of
Dysferlin in monocytes.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>25. Usha K Ramachandran, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>School of Biological and Biomedical Sciences, University of
Durham, South Road, Durham, UK</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>usha.Ramachandran@durham.ac.uk<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Enhancing Dysferlin Research:
Generation and Characterization of Muscle Cell Lines Knocked Down for Dysferlin
and Myoferlin.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Usha K Ramachandran <sup>1</sup>, Gareth Marlow <sup>1</sup>,
Joshua Zimmerberg <sup>2</sup>, Michelle M Maxwell <sup>3</sup>, Rumaisa Bashir
<sup>1</sup></span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> <br>
<span class=affiliations1><sup>1</sup>School of Biological and Biomedical
Sciences, University of Durham, South Road, Durham, UK; <sup>2</sup>National
Institute of Child Health and Human Development; NIH, Bethesda, MD, USA; <sup>3</sup>MassGeneral
Institute for Neurodegenerative Disease, Massachusetts General Hospital and
Harvard Medical School, Charlestown, MA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;                                          </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=128
src="poster-abstracts-images/image011.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=48"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>The availability of muscle cell lines showing dysferlin deficiency
is required to examine the role of dysferlin and in the future to test any
emerging therapies. Recently Robert Brown and Michelle Maxwell generated a
non-clonal C2C12 cell line stably expressing dysferlin shRNA plasmids to knock
down dysferlin expression. We have performed single cell cloning of this
non-clonal dysferlin deficient C2C12 cell line and selected several clones
showing extensive dysferlin knockdown. We have propagated one clone showing
&gt;90% dysferlin knockdown by Western blotting and cultures are available for
dysferlin researchers worldwide. This cell line is being characterized and the
data from this will be presented in a poster. In parallel we have also taken
the A/J cell line generated by Joshua Zimmerberg and colleagues and performed
myoferlin knockdown using pSUPER plasmids. We have previously used these
plasmids to generate a C2C12 myoferlin knockdown clonal cell line. Our progress
on the development of the dysferlin and myoferlin deficient muscle cells will
also be discussed. These cell lines will provide useful resources to examine
the role of dysferlin in muscle. </span></p>

<h1 style='margin-top:0in'><span lang=EN-GB style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif";color:#0D0D0D;font-weight:normal'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>27. Isabelle Richard, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, CNRS, Evry, France</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>richard@genethon.fr<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:windowtext'>Characterization of the
BLA/J Mice</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>William
LOSTAL <sup>1</sup>, Nathalie BOURG <sup>1</sup>, Carinne Roudaut<sup>1</sup>,
Isabelle RICHARD <sup>1</sup>, </span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'><br>
<span class=affiliations1><sup>1</sup>Généthon, CNRS, Evry, France</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=114
src="poster-abstracts-images/image012.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=6"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'> To
obtain a dysferlin deficient model that could be compared with a strain-matched
control, A/J strain, a naturally occurring mouse model of dysferlin deficiency
was backcrossed onto the C57BL/6 background. The A/J mutation is a
retrotransposon insertion in intron 4 that leads to out-of frame aberrant
splicing and absence of the dysferlin protein. This model, B6.A/J-<i>Dysf<sup>prmd</sup></i>
(<i>Dysf<sup>prmd</sup></i>), was characterized at 1, 2 and 4 months of age.
Homozygous mice presented with their first dystrophic features at 2 months of
age and worsened by 4 months of age as indicated by the presence of
centronucleated fibers and areas of inflammation. The majority of muscles were
impaired with <i>Psoas</i> being the most affected, followed by <i>Quadriceps
femoris</i> and <i>Tibialis anterior</i> and then <i>Gastrocnemius</i>.
Immunohistochemistry using a RyR antibody showed that the structure of the
T-tubule is conserved in the <i>Dysf<sup>prm</sup></i>mice. Comparison of <i>Dysf<sup>prmd</sup></i><sup>
</sup>with A/J mice of the same ages showed that backcrossing onto C57BL/6
maintains the deleterious character of the A/J mutation at a comparable level
to that seen on the natural background </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>31. John M. Robinson, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology and Cell Biology, Ohio State University,
Columbus, OH, USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:robinson.21@osu.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>robinson.21@osu.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Generation of Chicken
Antibodies to Dysferlin</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>John M. Robinson <sup>1</sup>, Dale D. Vandre <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology and Cell
Biology, Ohio State University, Columbus, OH, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=105 height=128
src="poster-abstracts-images/image013.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=55"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>A total of 14 unique dysferlin transcript variants have been
identified. Of these, 7 variants are generated using the promoter designated
DYSF (Dysf var 1 through 7), and 7 variants from the promoter designated
DYSF_v1 (Dysf var v1_1 through v1_7). Currently available antibody reagents
recognize all dysferlin isoforms and do not discriminate between these variant
isoforms. Therefore, antibody reagents that differentiate between dysferlin
isoform types would be useful to initiate studies designed to determine the
functional properties of individual dysferlin isoforms. To begin addressing
this problem, we have attempted to generate and characterize chicken IgY
antibodies that can discriminate between dysferlin isoforms containing the
corresponding DYSF or DYSF_v1 N-terminal amino acid sequence. Six unique
synthetic peptides were generated, and were used as immunogens in chickens
following coupling to keyhole limpet hemocyanin. Two peptides were derived from
each of the unique dysferlin N-terminal sequences, and two control peptides
were derived from sequences common to all dysferlin isoforms. Chicken IgY
antibodies were purified from the yolk of eggs obtained from immunized hens,
and were screened by immunoblot analysis against tissue and cell extracts known
to contain dysferlin. Preliminary results indicated that the crude IgY
preparations required additional purification, and affinity purification
against the immunizing synthetic peptides was undertaken. Analysis of the
affinity purified antibodies is ongoing using the human trophoblast BeWo cell
line as a model to screen the affinity purified antibodies. In BeWo cells,
dysferlin is expressed following forskolin-induced cell fusion. While this
characterization is continuing, we have demonstrated that chicken dysferlin
antibodies have been generated that recognize all dysferlin isoforms. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><b><span style='font-size:12.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:navy'>33. Daniel
Stockholm, PhD</span></b></p>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, 1, rue de l’Internationale, 91000 Evry, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>stockho@genethon.fr<span
style='color:black'> </span></span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Comparison of Membrane Repair
Response in Myoblasts, Myotubes and Myofibers of Two Dysferlin-Deficient Mouse
Models Using the Laser Wounding Assay</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Sébastien Henin <sup>1</sup>, Perrine Borel <sup>1</sup>, William
Lostal <sup>1</sup>, Nathalie Bourg-Alibert <sup>1</sup>, Isabelle Richard <sup>1</sup>,
Daniel Stockholm <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Généthon, 1, rue de l’Internationale,
91000 Evry, France</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=138
src="poster-abstracts-images/image014.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=29"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Dysferlin in the muscle fiber has been shown to be an important
mediator of plasma membrane repair. New therapeutic approaches are presently
developed to compensate for dysferlin-deficiencies. However, a variety of
dysferlinopathies mouse models are available as well as a large panel of
functional tests to evaluate the membrane repair process. Recently, surprising
results showed different membrane repair defect in cultured dysferlin-deficient
myotubes (derived from two different dysferlin-deficient cell lines) compared
with isolated myofibers from dysferlin-deficient mice. The role of dysferlin in
various cellular models is in fact not clearly elucidated. In order to clarify
the effect of cell culture, differentiation and the type of mutation on the membrane
repair defect, we use the laser wounding assay to compare in two different
models (BlaJ and the Dysf KO mouse) the potential of membrane repair in
isolated myofibers and cultured cells (primary myoblasts and myotubes). For
this purpose, we are currently performing a blind study to assess the
reliability of the laser wounding technique both on isolated fibers from FDB
muscle and primary cultured myoblasts and myotubes derived from the three mouse
strains (BlaJ, DysfKO and C57Bl6). The complete analysis should allow us both
to determine how reproducible the laser protocol itself can be and how
effective the repair response is in our different conditions.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal align=center style='margin-bottom:3.0pt;text-align:center'><b><span
style='font-size:18.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Poster Session II:</span></b></p>

<p class=MsoNormal align=center style='margin-bottom:3.0pt;text-align:center'><b><span
style='font-size:18.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></b></p>

<h1 style='margin-top:0in'><span lang=ES-MX style='font-size:12.0pt;line-height:
115%;font-family:"Helvetica","sans-serif";color:navy'>2. Florian Barthelemy</span></h1>

<p><span class=affiliation11><span lang=ES-MX style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'>INSERM UMR_S 910-Universite
de la Mediterranee-Faculté de Médecine de la Timone-27 bd Jean Moulin- 13385
Marseille cedex 05</span></span><span lang=ES-MX style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
<span class=email>florian.barthelemy@univmed.fr</span> </span></p>

<h2 style='margin-top:9.0pt'><span lang=ES-MX style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&quot;Mini-Proteins&quot;
Approaches For Dysferlinopathies</span></h2>

<p><span class=authors1><span lang=ES-MX style='font-size:9.0pt;font-family:
"Helvetica","sans-serif";color:black'>Florian Barthelemy <sup>1</sup>, Nicolas
Wein <sup>1</sup>, Virginie Kergourlay <sup>1</sup>, Nicolas Levy <sup>1</sup>,
Martin Krahn <sup>1</sup>, Marc Bartoli <sup>1</sup></span></span><span
lang=ES-MX style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'> <br>
<span class=affiliations1><sup>1</sup>INSERM UMR_S 910-Universite de la
Mediterranee-Faculté de Médecine de la Timone-27 bd Jean Moulin- 13385
Marseille cedex 05</span> </span></p>

<p><span lang=ES-MX style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=74 height=86
src="poster-abstracts-images/image015.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=32"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Dysferlin is composed of several homologous C2 domains and a
domain specific to dysferlin with unknown function: Dysf N and C. These C2
domains differ from each other by their function and/or the interaction
established with dysferlin partners. For example, the first C2 domain (C2A) of
dysferlin can interact with several partners, and notably with alpha-tubulin
and AHNAK. Similarly, we demonstrated that the last C2 domains (C2F and G)
together with the transmembrane domain were sufficient to induce membrane
repair. The approaches proposed here will consist in improving the naturally
identified “mini-dysferlin” by creating several “midi-dysferlin”, carrying
different domains of dysferlin. This study will be important not only for
therapeutic strategy but also for understanding the various functions of
dysferlin. For gene transfer in a mouse model of dysferlinopathy we plan to use
AAV derived vectors. These AAVs are currently the best vectors for muscle
targeting and have proven very useful in neuromuscular gene transfer. The
number of C2 domains that could be expressed by an AAV cassette containing the
C5-12 promoter is around three domains. We postulate that any C2 domains of
dysferlin and the transmembrane domain of dysferlin will be sufficient for
membrane repair. Adding the C2A domain that is engaged in several interactions
would be important to address and regulate these mini-proteins. So we have
already cloned several of these: C2A-C2F-C2G; C2A-C2G; C2F-C2G. Those
mini-proteins were expressed and stable. We are currently testing the
localization/interaction and membrane repair capability of these mini-proteins.
The poster will present the latest data obtained and the perspective of our
work. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>4. Rumaisa Bashir, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>School of Biological and Biomedical Sciences, University of
Durham, South Road, Durham, UK;</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
<span class=email>rumaisa.bashir@durham.ac.uk</span> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Evidence of Release of
Nano-Membranes from C2C12 Muscle Myotubes: Therapeutic Implications? </span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Usha K Ramachandran <sup>1</sup>, Khalil Saleki <sup>1</sup>,
Rumaisa Bashir <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>School of Biological and Biomedical
Sciences, University of Durham, South Road, Durham, UK;</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=101
src="poster-abstracts-images/image016.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=49"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Immunofluorescence analysis of C2C12 myotubes is a routine
experiment in our laboratory to determine the expression and distribution of a
variety of muscle proteins. Whilst performing confocal analysis of
immunolabelled C2C12 myotubes we have consistently identified cytoplasmic
vacuolar regions. To gain insights into their origin we performed confocal
imaging, live cell imaging and EM analysis to demonstrate that the vacuolar
regions are sites of membrane shedding. Membrane bound organelles resembling
multivesicular body like structures are released from C2C12 myotubes. We
demonstrate that the shedding of these nano-organelles can be enhanced by
cholesterol depletion. We have stained these organelles with different
antibodies to a variety of muscle membrane proteins. Positive staining is
detected for dysferlin, myoferlin, caveolin-3 and </span><span
style='font-size:9.0pt;line-height:115%;font-family:Symbol;color:black'>a</span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>-dystroglycan. EM analysis confirms that these nano-organelles are
released from C2C12 myotubes by outward budding of the myotube membrane. Our
results indicate that C2C12 myotubes are active in membrane shedding. We
propose that these structures may provide a natural source of muscle cell
membrane and consequently may be suitable for the delivery of muscle proteins
such as dysferlin. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>6. Glen W Humphrey, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Program in Physical Biology, National Institute of Child Health
and Human Development, Bethesda, MD, USA</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:humphreg@mail.nih.gov"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>humphreg@mail.nih.gov</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Effect of Phospholipid Fatty
Acid Modification on Dysferlin-independent Membrane Resealing.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Glen W Humphrey <sup>1</sup>, Elena Mekhedov <sup>1</sup>,
Alexandr Chanturiya <sup>1</sup>, Paul S Blank <sup>1</sup>, Joshua Zimmerberg <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Program in Physical Biology, National
Institute of Child Health and Human Development, Bethesda, MD, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=104 height=106
src="poster-abstracts-images/image017.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=67"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Mutations in the dysf gene coding for dysferlin cause late-onset
muscle wasting syndromes in humans and mice (e.g. Myoshi myopathy and LGMD2b).
The muscle wasting disease is thought to be due to loss of a dysferlin
dependent, calcium-activated plasma membrane repair process. According to
lipidic pore theory, membrane resealing should depend on the 3D shape of the
phospholipids. Conical phospholipids (e.g. small headgroup and large fatty acid
tails), supporting higher line tension, should favor spontaneous pore
resealing. For therapy, we propose that dietary lipids can change muscle plasma
membrane composition in ways that alter the line tension of a lipidic pore. We
are testing this therapy paradigm by increasing the content of polyunsaturated
fatty acids (PUFA) in plasma membrane lipids to improve the stability of muscle
cell membranes in muscles lacking dysferlin. To increase the PUFA content of
membrane phospholipids, myotubes are cultured with exogenous PUFA
supplementation (docosahexaenoic acid [DHA], 22:6, n-3). We have designed an
assay for membrane repair in cultured myotubes and isolated muscle fibers,
maintained under physiological conditions. Cells are subjected to IR laser
wounding, and changes in intracellular [Ca2+] are monitored using fluorescent
indicators. A lower level of laser irradiation produces a transient increase in
[Ca2+] at the wound site, scored as resealing, while higher levels produce a
persistent increase (or loss of indicator) scored as no resealing. DHA supplementation
decreased the sensitivity of myotubes to laser wounding (compared to ethanol
control). However, ethanol alone increased the sensitivity to wounding
suggesting that the DHA effect is more robust.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>8. Pradeep Gonugunta Kumar, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Neurology, Nizam's Institute of Medical Sciences,
Hyderabad, India</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:GPK_MBBS@YAHOO.COM"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>gpk_mbbs@yahoo.com</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Clinico-Pathological Profile
of Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>P G Kumar <sup>1</sup> Meena A K <sup>1</sup>, Sundaram C <sup>2</sup>,
Megha S Uppin <sup>2</sup>, Krishna Lsr <sup>3</sup>, Rupam Borgohain <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department Of Neurology, Nizam's
Institute of Medical Sciences, Hyderabad, India; <sup>2</sup>Department Of
Pathology, Nizam's Institute of Medical Sciences, Hyderabad, India; <sup>3</sup>Department
Of Cardiology, Nizam's Institute of Medical Sciences, Hyderabad, India;</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=115 height=93
src="poster-abstracts-images/image018.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=56"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>BACKGROUND: Dysferlinopathies are autosomal recessive limb girdle
muscular dystrophies (LGMD) with protean manifestations. We describe
clinicopathological findings in 34 LGMD patients. METHODS: Consecutive patients
with features of muscular dystrophy attending neuromuscular disorder clinic at
a tertiary care hospital in south India were evaluated from January 2006 to May
2010. Neurological and electrophysiological examination, creatine kinase (CK),
electrocardiogram, 2D-echocardiography &amp; muscle biopsy for histopathology
and immunohistochemistry (IHC) were done. RESULTS: On IHC 36 patients,
diagnosed to have Dysferlinopathy, had M: F ratio 21:15, mean age at
presentation 26.26 yrs and consanguinity history in 9(25%). Proximal weakness
was seen in 35.29%, proximo-distal in 50 %, &amp; distal in 11.76% patients. 1
patient had isolated right ventricular dilated cardiomyopathy with atrial
fibrillation. Myalgia was seen in 7 patients (20.58%). Muscle imaging (8
patients) showed involvement of tibialis anterior, peronei muscles in 4,
gastrosoleus in 2 &amp; mixed quadriceps and anterior tibial group in 2
patients. CK was elevated in 22 (61.11%) &amp; myopathic potentials in 32
patients (88.23%). Biopsy showed dystrophic features with inflammation in 22.22
% &amp; rimmed vacuoles in 30.55%. 4 patients with inflammation, diagnosed as
inflammatory myopathy initially, received steroids. Significant response was
seen in 3 but had persistent weakness &amp; high CK levels. CONCLUSION:
Dysferlinopathy commonly presents as proximal myopathy with occasional distal
involvement. It occurs commonly in males. Right ventricular dilated
cardiomyopathy may be a sole presenting feature. CK is usually elevated.
Steroids may be useful, especially in patients with inflammation on biopsy.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>10. Steve Laval, DPhil</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Institute of Human Genetics, Newcastle University, UK</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:s.h.laval@ncl.ac.uk"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>s.h.laval@ncl.ac.uk</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>A Founder Mutation in
Anoctamin 5 is a Major Cause of Limb Girdle Muscular Dystrophy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Debbie Hicks <sup>1</sup>, Anna Sarkozy <sup>1</sup>, Nuria Muelas
<sup>2</sup>, Katrin Kohler <sup>3</sup>, Angela Huebner <sup>3</sup>, Gareth
Hudson <sup>4</sup>, Rita Barresi <sup>5</sup>, Michelle Eagle <sup>1</sup>,
Tuomo Polvikoski <sup>4</sup>, Geraldine Bailey <sup>6</sup>, James Miller <sup>7</sup>,
Aleksander Radunovic <sup>8</sup>, Paul J Hughes <sup>9</sup>, Richard Roberts <sup>10</sup>,
Sabine Krause <sup>11</sup>, Maggie C Walter <sup>11</sup>, Steve H Laval <sup>1</sup>,
Volker Straub <sup>1</sup>, Hanns Lochmuller <sup>1</sup>, Kate Bushby <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Institute of Human Genetics, Newcastle
University, UK; <sup>2</sup>Department of Neurology, Hospital Universitario La
Fe, Valencia, Spain; <sup>3</sup>Children's Hospital, Technical University
Dresden, Dresden, Germany; <sup>4</sup>Institute for Ageing and Health,
Newcastle University, UK; <sup>5</sup>Muscle Immunoanalysis Unit, Newcastle
upon Tyne Hospitals Trust, Newcastle, UK; <sup>6</sup>Northern Genetic Service,
Institute of Human Genetics, Newcastle upon Tyne, UK; <sup>7</sup>Department of
Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK; <sup>8</sup>The
Royal London Hospital, London, UK; <sup>9</sup>Hurstwood Park Neurological
Centre, Haywards Heath, West Sussex, UK; <sup>10</sup>Ninewells Hospital &amp;
Medical School, Ninewells, Dundee, UK; <sup>11</sup>Friedrich Baur Institute,
Ludwig-Maximilians University, Munich, Germany</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=75
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=2"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=2"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>In addition to mutations in dysferlin, LGMD2B and Miyoshi myopathy
(MM) can have other genetic causes. Understanding the genetic basis and
clinical course of these non-dysferlin LGMD2B/MM cases may accelerate
understanding of the pathological process in dysferlinopathy. Recently,
mutations in the ANO5 gene, which encodes a putative calcium-activated chloride
channel belonging to the Anoctamin family of proteins, were identified in 5
families with one of two previously identified disorders, non-dysferlin Miyoshi
muscular dystrophy (MMD3) and LGMD2L. We screened a candidate group of 64
patients from 59 British and German kindreds and found the truncating mutation,
c.191dupA in exon 5 of ANO5 in 20 patients. An intragenic SNP and an extragenic
microsatellite marker are in linkage disequilibrium with the mutation,
suggesting a founder effect in the Northern European population. We have
further defined the clinical phenotype of ANO5- associated muscular dystrophy.
Patients show adult onset proximal lower limb weakness with highly raised CK
values (average 4500 IU/L) and frequent muscle atrophy and asymmetry of muscle
involvement. Upper limb muscle function is only mildly affected and cardiac and
respiratory function is normal. Females appear less frequently affected. In the
North of England population we have identified 8 patients with ANO5 mutations,
suggesting a minimum prevalence of 0.27/100 000, twice as common as
dysferlinopathy. We suggest that mutations in ANO5 represent a relatively
common cause of adult onset muscular dystrophy with high CK and that mutation
screening, particularly of the common mutation c.191dupA, should be an early
step in the diagnostic algorithm of adult MM and LGMD patients.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>12. Yun-Sil Lee, DDS, MS</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Molecular Biology &amp; Genetics, Johns Hopkins
Univ. School of Medicine, Baltimore, MD, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:yunlee@jhmi.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>yunlee@jhmi.edu</span></span></a><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Increasing Muscle Mass by
Follistatin and Acvr2B/Fc in Dysferlin Mutant Mice</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Yun-Sil Lee <sup>1</sup>, Se-Jin Lee <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Molecular Biology &amp;
Genetics, Johns Hopkins Univ. School of Medicine, Baltimore, MD, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><img width=100 height=98
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=58"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=58"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black;font-weight:normal'>Myostatin (MSTN), a member of the TGF-beta
super-family, is a negative regulator of skeletal muscle mass. Therefore, agents
capable of blocking the myostatin signaling pathway could have important
applications for treating patients with muscle degenerative diseases. Various
myostatin-binding proteins have been identified as myostatin inhibitors in in
vitro studies. Two of these proteins, follistatin and a soluble form of the
Acvr2B receptor (Acvr2B/Fc), have been shown to be capable of increasing muscle
mass when expressed as a transgene in muscle or administered in purified form
to mice. To develop the potential therapeutic agents to promote muscle growth
and regeneration in patients with dysferlin deficiency, we are examining the
effects of the follistatin transgene expression and Acvr2B/Fc administration in
dysferlin mutant mice. We believe that these studies will provide valuable
information regarding the potential benefits of this therapeutic strategy in
patients with limb-girdle muscular dystrophy type 2B and Miyoshi myopathy.</span></h1>

<p class=MsoNormal>&nbsp;</p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>14. William Lostal, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Genethon, CNRS, 1, rue de l’Internationale, 91000 Evry, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:lostal@genethon.fr"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>lostal@genethon.fr</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify;line-height:normal'><b><span lang=EN-GB style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify;line-height:normal'><b><span lang=EN-GB style='font-size:9.0pt;
font-family:"Helvetica","sans-serif"'>Efficient <i>in vivo</i> Dysferlin
Expression by Dual AAV Vector Reconstruction.</span></b></p>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>William Lostal <sup>1</sup>, </span></span><span lang=EN-GB
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Nathalie Bourg<sup>1</sup>,
Carinne Roudaut<sup>1</sup>, Katsuya Miyake<sup>2</sup>, Paul McNeil<sup>2</sup>,
Marc Bartoli<sup>1</sup> and Isabelle Richard<sup>1</sup></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Genethon, CNRS, 1, rue de
l’Internationale, 91000 Evry, France;</span> <span class=affiliations1><sup>2</sup></span></span><span
lang=EN-GB style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Medical
College of Georgia, Augusta, Georgia, USA</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;text-align:
justify;line-height:normal;text-autospace:none'><img width=100 height=123
src="poster-abstracts-images/image019.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=33"><span
lang=EN-GB style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>C</span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>onsidering the
recessive nature of dysferlinopathies, a possible therapeutic strategy is gene
transfer. To date, the best vector for gene transfer in muscle is Adeno
Associated Virus (AAV). However, the human dysferlin cDNA size of 6.2 kb,
preventing its direct incorporation into a single AAV vector, since the
encapsidation limit is around 4.7 kb. In order to bypass this limitation, we
set up a strategy taking advantage of the concatemerization ability of AAV
vectors. </span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>The
dysferlin cDNA was separated into two rAAV vectors; one carrying a muscle
specific promoter followed by the 5’ half of dysferlin cDNA and a 5’ splicing signal and another one carrying a 3’ splicing signal, the remaining dysferlin sequence
and a polyadenylation signal. To test this <i>in vivo</i> approach<i>,</i>
intramuscular injection of both vectors was performed into dysferlin deficient
mice. Full-length dysferlin mRNA was correctly spliced, expressed at a level
close to the endogenous one and was stable for an entire year. At the protein
level, dysferlin was detected at 237 kDa, the size of the expected full-length
protein. This expression was associated with an improvement of the histological
aspect of the muscle, a reduction in the number of necrotic fibers, restoration
of membrane repair capacity and a global improvement in locomotor activity was
observed after systemic injection. Altogether, these data support the use of
such a strategy for the treatment of dysferlin deficiency.</span></p>

<p class=MsoNormal>&nbsp;</p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>16. Katie Maguire, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Neurology, Stanford University, Palo Alto, CA, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:kmag@stanford.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>kmag@stanford.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Gene Editing of Dysferlin </span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Katie Maguire <sup>1,2</sup>, Thomas Rando <sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Neurology, Stanford
University, Palo Alto, CA, USA; <sup>2</sup>Veterans Affairs Health Care
System, Palo Alto, CA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=139
src="poster-abstracts-images/image020.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=60"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Limb Girdle Muscular Dystrophy 2B and Miyoshi Myopathy (LGMD2B/MM)
are diseases of muscle caused by mutations in the dysferlin gene, which encodes
a large membrane-associated protein important for calcium-mediated membrane
fusion. The majority of genetic mutations that cause LGMD2B are single point
mutations or small insertions/deletions. Gene editing is a method of gene
therapy in which synthetic, modified single-stranded oligonucleotides are
designed to alter single bases and may therefore potentially be used to correct
mutant bases within the dysferlin gene. Here we demonstrate gene editing of a
single base within a patient-derived myoblast cell line. An oligonucleotide was
designed to edit a transition (G&gt;A) mutation within exon 44, thereby
restoring the wild-type Glycine at amino acid position 1628. The correction of
this mutation was assessed by a sensitive ARMS PCR assay in which primers are
designed to specifically detect the edited form of the gene. We also show the
restoration of dysferlin protein by immunofluorescence analysis. These data
demonstrate that single-stranded oligonucleotides are capable of correcting
point mutations in human dysferlin ex vivo, which has the potential to be used
as a therapeutic approach in treating LGMD2B. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>18. François Monjaret, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Généthon, CNRS, 1, rue de l’Internationale, 91000 Evry, France</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:fmonjaret@genethon.fr"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>fmonjaret@genethon.fr</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Trans-Splicing Approach for
Dysferlinopathies.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>François Monjaret <sup>1</sup>, Karine Charton <sup>1</sup>,
Isabelle Richard <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>généthon, Cnrs, 1, Rue De
L’internationale, 91000 Evry, France</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=135
src="poster-abstracts-images/image021.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=12"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Alternative strategies can be tested in a therapeutic perspective
on dysferlinopathies, such as RNA reprogramming by spliceosome-mediated RNA
trans-splicing. This strategy would have the advantage to bypass the
possibility of any toxicity related to dysferlin over-expression since the
endogeneous transcriptional control is conserved. In addition, it would be
applicable to any type of mutations except very large deletions. To obtain a
proof of feasibility on human cells, we constructed a pre-mRNA trans-splicing
molecule (PTM) comprising a binding domain hybridizing part of intron 48, the
exons 49-55 coding region and a FLAG epitope. We also constructed a human
dysferlin minigene from exons 47 to 55 to be used as trans-splicing target.
Following co-transfection of these constructs in HER911 cells, we validated
transcription of the minigene and PTM by RT-PCR. Using primers corresponding to
the trans-spliced molecules, we observed an intense band at the expected size,
demonstrating that trans-splicing had occurred. Western Blot analysis using
FLAG antibody to detect specifically the trans-spliced protein showed a band of
the predicted size, indicating that the trans-spliced RNA has been translated.
Additional protein bands were also detected which probably correspond to
trans-splicing on endogeneous dysferlin pre-messenger expressed by HER911
cells. Following these preliminary results, we will test this PTM on human
myogenic cells from dysferlin patients. We are also evaluating this strategy to
reverse the pathological signs observed in the dysferlin-deficient mouse model.
Several PTMs have been constructed and are being validated <i>in vitro</i> on
the endogeneous dysferlin expressed in murine myogenic C2 cells, before <i>in
vivo</i> AAV-mediated transfection. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>20. Vincent Mouly, PhD</span></h1>

<p><i><span lang=FR style='font-size:9.0pt;font-family:"Helvetica","sans-serif"'>Institut
de Myologie, UM76 -&nbsp;UPMC Univ. Paris 6, Paris, France</span></i></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>vincent.mouly@upmc.fr</span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Immortalized Human Dysferlin
Cells: A Tool to Assess Pathophysiology and Therapeutic Strategies</span></h2>

<p class=MsoNormal style='text-autospace:none'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>A. Bigot<sup>1</sup>, V.
Mouly<sup>1</sup>, S. Chaouch<sup>1</sup>, N. Wein<sup>2</sup>, K. Mamchaoui<sup>1</sup>,
C. Trollet<sup>1</sup>, , E. Negroni<sup>1</sup>, A. Wolff<sup>1</sup>, D.
Furling<sup>1</sup>, N. Levy<sup>2</sup>, S. Spuler<sup>3</sup>, T. Voit<sup>1</sup>,
W.E. Wright<sup>4</sup>, A. Aamiri<sup>5</sup> &amp; G.S. Butler-Browne<sup>1</sup><span
style='color:black'><br>
<span class=affiliations1><sup>1</sup></span></span></span><span lang=FR
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
Thérapie des maladies du muscle strié / Institut de Myologie, UM76 -&nbsp;UPMC
Univ. Paris 6 / U974 - Inserm&nbsp;/ UMR7215 –&nbsp;CNRS, Paris, France</span><span
class=affiliations1><span lang=FR style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>; <sup>2</sup></span></span><span
lang=FR style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
Faculté de Médecine de Marseille, Université de la Méditerranée, Inserm UMRS
910 Génétique Médicale et Génomique Fonctionnelle, Marseille, France; </span><span
lang=FR style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'> <span class=affiliations1><sup>3</sup></span></span><span
lang=FR style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
Experimental and Clinical Research Center (ECRC), Charité, University Medicine
Berlin, Germany; </span><span class=affiliations1><sup><span lang=FR
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>4</span></sup></span><span lang=FR style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>Southwestern Medical
Center, Department of Cell Biology, Dallas, TX 75390, USA</span><span
class=affiliations1><span lang=FR style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>; <sup>5</sup></span></span><span
lang=FR style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>
</span><span lang=FR style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Laboratoire
LBCM, Dept de Biologie, Faculté des Sciences, Agadir, Maroc</span></p>

<p><span lang=FR style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=104 height=123
src="poster-abstracts-images/image022.jpg"
align=left hspace=12 alt="Description: V_Mouly"><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'> </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>We
recently generated immortalized human myoblast cell lines from control donors,
by transduction of these cells with both telomerase (hTERT) and
cyclin-dependent kinase 4 (CDK-4) expressing vectors (recombinant retro- and
lentiviruses). These cells maintain their potential to differentiate both in
vitro and in vivo, and are not tumorigenic (Zhu, Mouly et al 2007). We have now
generated human myoblast cell lines from dysferlin deficient patients (LGMD2B)
using the same approach, as well as fibroblast cell lines which only requires
hTERT transduction. Fibroblasts can be easily isolated and then converted by
transduction of an inducible MyoD expression vector (lentivirus). Such
converted fibroblasts have been used to assess exon skipping strategy for
dysferlin deficiency (Wein et al 2010). We have also now generated 6 LGMD2B
myoblast  cell lines with different mutations. These cell lines are either
heterozygous or homozygous and represent different possibilities for
therapeutic strategies. Interestingly, while all of these cell lines are
available to academic researchers, one cell line has all the informed consent
required for private companies willing to develop therapeutic tools for LGMD2B.
We have also generated fibroblast cell lines transduced for inducible MyoD for
most of these mutations, which can be  valuable since these have only one resistance
gene (Puromycin), thus making transduction with for instance resistance to
neomycin possible. Their capacity to differentiate in vitro as well as their
proliferative potential were monitored for all these cell lines. Furthermore,
their capacity to participate to in vivo regeneration was assessed for some of
these cell lines, by injecting them into regenerating TA muscles of
immunodeficient mice.</span><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif"'> </span><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>All these cell lines
represent useful tools to assess pathophysiology for this disease in which,
although the mutation is known, the mechanisms leading to the pathology are not
always clear. They represent valuable tools to assess tailored or general
therapeutic strategies, depending on the targeted mutation. More cell lines are
currently being developed, and these cell lines can be shared with the
scientific community on a collaborative basis. </span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>22. Maura Parker, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Clinical Research Division, Fred Hutchinson Cancer Research
Center, Seattle, WA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:mparker@fhcrc.org"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>mparker@fhcrc.org</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Quantitative Comparison of
Cell Engraftment in Regenerating Skeletal Muscle</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Maura H. Parker <sup>1</sup>, Carol Loretz <sup>1</sup>, Rainer
Storb <sup>1,3</sup>, Stephen J. Tapscott <sup>2,4</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WA; <sup>2</sup>Human Biology
Division, Fred Hutchinson Cancer Research Center, ; <sup>3</sup>Department of
Medicine, University of Washington, Seattle, WA, ; <sup>4</sup>Department of
Neurology, University of Washington</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=101
src="poster-abstracts-images/maura-parker.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=57"><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>Muscle-derived
cell transplantation has the potential to effectively treat many human
diseases, including muscular dystrophy. Studies in mdx mice demonstrate that
normal muscle-derived cells engraft into skeletal muscle, effectively restore
dystrophin expression and reconstitute the satellite cell pool. However, immune
rejection of donor cells prevented long-term engraftment in human trials. We
have induced immune tolerance in cxmd canines using a clinically relevant
regimen of bone marrow transplantation, and show donor muscle-derived cell
engraftment and survival for at least 24 weeks in the absence of
immunosuppression. In addition to the immune tolerant cxmd model, we have
developed a canine-to-mouse xenotransplantation model to rapidly and
quantitatively compare canine muscle cell engraftment. The canine-to-mouse
model allows us to quantitatively compare cell populations and modulating
factors, and establish priority for canine-to-canine transplantation
experiments. Specifically, we have used the xenotransplant model to demonstrate
that canine muscle derived cells sorted for expression of CXCR4 do not display
a greater level of engraftment when compared to a mixed cell population.
However, pre-treating a mixed cell population with diprotin A, a positive
modulator of CXCR4-SDF-1 binding, enhances engraftment, both to the muscle
fiber pool and the satellite cell population. Further studies will establish
the best protocols for muscle cell transplantation and lead to future human
clinical trials of muscle cell transplants for the treatment muscular
dystrophies. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>24. Morayma Reyes, MD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Pathology, Univ. of Washington, Seattle, WA, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:morayma@uw.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>morayma@uw.edu</span></span></a><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Sphingosine 1 Phosphate
Ameliorates Muscular Dystrophy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Morayma Reyes <sup>1</sup>, Nicholas Ieronimakis <sup>1</sup>,
Hannele Ruohola-Baker <sup>2</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Pathology, Univ. of
Washington, Seattle, WA, USA; <sup>2</sup>Department of Biochemistry, Univ. of
Washington, Seattle, WA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=100 height=101
src="http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=61"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=61"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Sphingosine 1 phosphate (S1P) is a bioactive lipid involved in
multiple cellular processes including cell division, proliferation, migration
and differentiation. S1P has been shown to aid muscle regeneration after acute
injury. We hypothesize, that because S1P signaling is important for muscle
regeneration, knockout mice for S1P receptors may exhibit impaired muscle
regeneration after acute injury. We have studied the expression of all three
S1P receptors in skeletal muscle perivascular cells (CD45-/CD31-/CD34+/Sca-1+).
Interestingly, perivascular cells express 100-200 folds higher levels of S1P
receptor 3 (R3) as compared to C2C12. Furthermore, the levels of R3 decrease
~50% on perivascular cells isolated from muscular dystrophy mice, mdx. We
studied the abundance, colony formation capacity and proliferation of satellite
cells and perivascular cells in R3 null mice compared to wt (n=3, per group).
In 2 of 3 R3 null mice, the abundance of perivascular cells was decreased ~50%
and their proliferation (number of cells in the first passage) was also
decreased. R3 null satellite cells (Sca-1-/CD45-/CD31-/alpha-7 integrin+/CD34+)
(Ieronimakis N, 2010) showed 3 folds decreased total number of cells and
numbers of colonies in culture. Thus we hypothesize that S1P administration may
help muscle repair especially in the setting of muscular dystrophy. S1P
administration in TA muscles of mdx mice after CTX injury showed increased
numbers of satellite cells (n=3). The lyase inhibitor (THI), which is a food
supplement, increases S1P levels. We are currently studying the effects of
systemic administration of THI in two mouse models of muscular dystrophy, mdx
and B6.A-Dysfprmd mice. If beneficial THI may have direct therapeutic
applications to treat dysferlinopathy.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>26. Joseph A Roche, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Physiology, University of Maryland School of
Medicine, Baltimore, MD, USA</span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:jroche@som.umaryland.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>jroche@som.umaryland.edu</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Physiological and
Histological Changes in Skeletal Muscle Following Electroporation.</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Joseph A Roche <sup>1</sup>, Diana L. Ford-Speelman <sup>1</sup>,
Lisa W Ru <sup>1</sup>,Allison L. Densmore<sup>1</sup>, Patrick W. Reed<sup>1</sup>, 
Robert J Bloch <sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Physiology, University of
Maryland School of Medicine, Baltimore, MD, 21201  USA</span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal><img width=100 height=100
src="poster-abstracts-images/image023.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=44"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Electroporation
(EP) is extensively used to transfect skeletal muscle fibers <i>in vivo</i>,
but its effects on the structure and function of skeletal muscle have not yet
been documented.  We studied the changes in histology and contractile function
after EP to determine the pattern of recovery, the extent of myofiber damage,
and the efficiency of transgene expression (GFP) in the tibialis anterior (TA)
muscle of male C57Bl/6J mice.  EP of exposed TA muscles followed standard
techniques.  Immediately after electroporation, contractile torque decreased by
~90% from pre-injury levels.  Within 3 hr, torque recovered to ~ 50% but stayed
low until d3.  Recovery then progressed slowly and was complete at d28.  In
muscles depleted of satellite cells by X-irradiation, torque remained low after
d3, suggesting that myogenesis is necessary for complete recovery.  Myogenic
activity was confirmed by an increase in fibers that labeled for developmental
myosin and showed central nuclei on d3. These features peaked at d14 and d28,
respectively, and persisted through d42.  Extensive myofiber damage was
confirmed by the presence of areas of necrosis infiltrated by CD68+
macrophages, which peaked between d3-7.  Damage persisted for long periods, as
fibers with central nuclei remained elevated at 1 yr after EP.  GFP expression
was detected at d3 and reached its maximum on d7.  The number of fibers
expressing GFP, the distribution of GFP+ fibers, and the signal intensity of
individual GFP+ fibers were highly variable.  We conclude that EP produces low
but highly variable levels of transfection, while causing extensive and
long-lasting myofiber damage, that requires myogenesis for recovery.  These
disadvantages render electroporation unsuitable for re-expressing dysferlin in
TA muscles of dysferlinopathic mice.  Supported by a fellowship to JAR and a
grant to RJB from the Jain Foundation.</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>28. Simone Spuler, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Muscle Research Unit, Experimental and Clinical Research Center,
Charité and Max Delbrück Center, Berlin, Germany</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:simone.spuler@charite.de"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>simone.spuler@charite.de</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Dysferlin Peptides Elicit
Functional Recovery in Dysferlinopathy</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Simone Spuler <sup>1</sup>, Verena Schöwel <sup>1</sup>, Andreas
Marg <sup>2</sup>, Anne Schulze <sup>1</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Muscle Research Unit, Experimental and
Clinical Research Center, Charité and Max Delbrück Center, Berlin, Germany; <sup>2</sup>Muscle
Physiology, Max Delbrück Center, Berlin, Germany</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=106 height=117
src="poster-abstracts-images/image024.jpg"
align=left hspace=12 alt="Description: sspuler photo"><span style='font-size:
9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";color:black'>Mutations
in dysferlin (DYSF) cause limb girdle muscular dystrophy 2B due to defects in
muscle membrane repair. More than 1300 mutations over the entire gene (DYSF)
have been identified. A third are missense mutations. Missense mutations within
the dysferlin gene (DYSF) can cause protein aggregation within the
endoplasmatic reticulum and amyloid deposits. We asked whether mutant dysferlin
can be redirected to the plasma membrane and whether it regains functionality
at this site. We used the pcDNA4/TO/MycHisB vector containing the full-length
human DYSF cDNA-GFP-tagged. We introduced three missense mutations
corresponding to DYSF p.G299R, DYSF p.L1341P, DYSF p.M2073V and transfected
them into C2C12 cells. Transfected C2C12 were treated with specifically designed
dysferlin-derived 10-12mer peptides coupled to the cell penetrating peptide
TAT. Dysferlin was localized by immunohistochemistry. All experiments were also
repeated in primary human myotubes carrying the respective DYSF mutations.
Membrane healing was assessed by two assays: 1) FM1-43 fluorescent dye entry
after laser- wounding of myotubes. 2) We introduced a new method that we call
interventional atomic force microscopy (iAFM) to apply defined sarcolemmal
injuries and to visualize repair on molecular level. 30 hours after application
of dysferlin-peptides mutant dysferlin could be detected at the sarcolemma of
C2C12 cells and in primary human myotubes from dysferlinopathy patients.
Primary human myotubes regained functionality in regard to membrane healing as
assessed by both approaches, laser wounding and iAFM. Thus, specific peptides
may allow for specific therapeutic targeting. </span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>29. Simone Spuler, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Muscle Research Unit, Experimental and Clinical Research Center,
Charité and Max Delbrück Center, Berlin, Germany</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:simone.spuler@charite.de"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>simone.spuler@charite.de</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Characterization of
Mstn-/-_BLA/J Double Mutant Mice</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Stephanie Adams <sup>1</sup>,</span></span><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif"'> Verena Schöwel<span
class=authors1><span style='color:black'> <sup>1</sup>, Stephanie Meier <sup>1</sup>,</span></span>
Andreas Marg<span class=authors1><sup><span style='color:black'>1</span></sup><span
style='color:black'>, Isabelle Richard <sup>2</sup>,</span></span> Se-Jin Lee<span
class=authors1><span style='color:black'> <sup>3</sup></span></span>, Simone Spuler<span
class=authors1><sup><span style='color:black'>1</span></sup></span><span
style='color:black'><br>
<span class=affiliations1><sup>1</sup>Muscle Research Unit, Experimental and
Clinical Research Center, Charité and Max Delbrück Center, Berlin, Germany; <sup>2</sup>Genethon,
France;<sup> 3</sup>Johns Hopkins University, Baltimore, MD, USA</span></span></span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><img width=106 height=117
src="poster-abstracts-images/image025.jpg"
align=left hspace=12 alt="Description: sspuler photo"><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif"'> Blockade of myostatin, a potent
inhibitor of  muscle growth, could be of benefit for treatment of muscular
dystrophies. We evaluated the effect of myostatin knockout on the course of
dysferlinopathy in BLA/J mice. We compared: 1) double mutant Mstn-/-_BLA/J
mice; 2) Mstn+/+_BLA/J; 3) Mstn-/-_C57BL/6; 4) C57BL/6. The following
parameters were taken: 1) endurance; 2) maximal force; 3) body composition; 4)
glucose metabolism; 5) oxygen consumption; 6) regenerative potential after
cardiotoxin; 7) laser wounding assay. Our results show that endurance at <i>young</i>
age was <i>better</i> in double mutants than in Mstn-/-_C57BL/6 mice.
Furthermore, regeneration after cardiotoxin injury was impaired in the absence
of <i>Mstn</i>. Differences in the laser wounding assay were not observed
between the groups. Data on aged animals will be available in two months. We
conclude, that inhibition of myostatin has no immediate benefit at young age in
dysferlinopathy in mice.</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif"'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>30. Mohan Viswanathan, PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Biology, MIT, Cambridge, MA, USA</span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'><br>
</span><a href="mailto:mohanv@mit.edu"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>mohanv@mit.edu</span></span></a><span style='font-size:
9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>A <i>C. elegans</i> Model of
Dysferlinopathy: Identification of Chemical and Genetic Suppressors of <i>C.
elegans </i>fer-1</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Mohan Viswanathan <sup>1,2</sup>, George Spracklin <sup>1,2</sup></span></span><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> <br>
<span class=affiliations1><sup>1</sup>Department of Biology, MIT, Cambridge,
MA, USA; <sup>2</sup>Cambria Pharmaceuticals, Cambridge, MA USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=95 height=84
src="poster-abstracts-images/image026.jpg"
align=left hspace=13 vspace=13
alt="Description: http://ankurdave.com/jainfoundation/conference2010/abstract-image.php?id=65"><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif";
color:black'>Mutations in fer-1, the C. elegans homolog of human dysferlin,
cause infertility. This infertility is the result of defective fusion of
intracellular vesicles, known as membranous organelles, to spermatocyte plasma
membrane, which is an otherwise obligate event in normal sperm maturation
required for fertility. The identification of mutations in homologous genes
conferring biologically similar defects in two different species strongly
suggests a conserved mechanism of function and provides the rational basis for
utilizing C. elegans fer-1 mutants as a biological model for human
dysferlinopathy. We have isolated chemical and genetic suppressors of the C.
elegans fer-1 mutant sterility phenotype in the hopes of exploiting the
conservation of biological function between fer-1 and dysferlin to ultimately
help identify compounds of therapeutic value. We have implemented a
high-throughput in vivo screen for small molecules capable of restoring
fertility to a C. elegans fer-1 mutant strain. We identified a number of hit
compounds, which have been tested in a secondary assay examining efficacy in
suppressing a second fer-1 mutant allele. Thus far, we have identified five structural
classes of chemical suppressors capable of suppressing sterility in two
different fer-1 mutants. We are expanding upon these structural scaffold
classes and plan to test these compounds in mammalian models of
dysferlinopathy. We have also performed a genetic screen isolating genetic
suppressors of the C. elegans fer-1 mutant sterility phenotype. Identification
of genetic suppressors may lead to the discovery of conserved genes with
potential as therapeutic targets. We have begun to characterize the genetic
suppressors, and have thus far identified one strong dominant suppressing
mutation outside of the fer-1 locus. </span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>32. Zipora Yablonka-Reuveni,
PhD</span></h1>

<p><span class=affiliation11><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Department of Biological Structure, Univ. of Washington, Seattle,
WA, USA</span></span><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'><br>
</span><a href="mailto:reuveni@u.washington.ed"><span class=email><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black;
text-decoration:none'>reuveni@u.washington.ed</span></span></a><span
style='font-size:9.0pt;font-family:"Helvetica","sans-serif";color:black'> </span></p>

<h2 style='margin-top:9.0pt'><span style='font-size:9.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:black'>Regenerative Superiority of
Satellite Cells from Extraocular Muscles</span></h2>

<p><span class=authors1><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>Quingwu W. Shen<sup>1</sup>, Irina Kirillova<sup>1</sup>, Lindsey
Muir<sup>2</sup>, Jeffrey Chamberlain<sup>2</sup>, Andrew Shearer<sup>1</sup>,
Zipora Yablonka-Reuveni<sup>1</sup></span></span><span style='font-size:9.0pt;
font-family:"Helvetica","sans-serif";color:black'><br>
<span class=affiliations1><sup>1</sup>Department of Biological Structure, Univ.
of Washington, Seattle, WA, USA; <sup>2</sup>Department of Neurology, Univ. of
Washington, Seattle, WA, USA</span> </span></p>

<p><span style='font-size:9.0pt;font-family:"Helvetica","sans-serif";
color:black'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><img width=93 height=107
src="poster-abstracts-images/image027.jpg"
align=left hspace=12 alt="Description: zipora"><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'> </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Extraocular
muscles (EOMs) develop from the head mesoderm and control eye movements. EOMs
are uniquely spared in muscular dystrophies resulting from dystrophin or
associated protein deficiency. </span><span style='font-size:9.0pt;line-height:
115%;font-family:"Helvetica","sans-serif"'>Specific traits of myogenic
progenitors in EOMs may play a role in the distinctions and preferential
sparing of these muscles. Surprisingly, very little is known about the myogenic
stem and progenitor cells in adult EOMs. We have focused on defining myogenic
cell sources in EOMs versus limb (LIMB) and diaphragm (DIA) muscles in the
mouse. Our view is that insights into the myogenic progenitors in EOMs versus
somite-derived body muscles may reveal cellular mechanisms of potential benefit
for combating muscle wasting in genetic disorders, disease and aging. We
concluded that in common with their LIMB and DIA counterparts, EOM satellite
cells are Pax7+, and express the nestin-GFP transgene and the Myf5nLacZ-knockin
reporter. Nevertheless, our cell culture studies indicate that EOM satellite
cells outperform their LIMB and DIA counterparts when compared in primary
cultures and clones for the magnitude of progeny production and contribution to
the reserve cell pool. Our pilot in vivo studies also indicate superior
engraftment of EOM satellite cells into host tibialis anterior muscles of mdx
mice. </span><span style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Our
results raise the possibility that EOM progenitors have superior potential for
use in cell-based therapy of muscle wasting disorders.  </span><span
style='font-size:9.0pt;line-height:115%;font-family:"Helvetica","sans-serif"'>Support:
NIH, MDA.</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<h1 style='margin-top:0in'><span style='font-size:12.0pt;line-height:115%;
font-family:"Helvetica","sans-serif";color:navy'>&nbsp;</span></h1>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-bottom:3.0pt'><b><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif"'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><b><span style='font-size:18.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:9.0pt;
line-height:115%;font-family:"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:9.0pt;line-height:115%;font-family:
"Helvetica","sans-serif";color:black'>&nbsp;</span></p>

</div>
